Logo Image
|Videos|September 21, 2022

Dr. Ornstein on antibody-drug conjugates for immunotherapy-refractory urothelial carcinoma

“The management of patients with advanced urothelial carcinoma whose cancer has progressed on immunotherapy presents a unique challenge,” says Moshe Ornstein, MD.

Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the emergence of antibody-drug conjugates as a treatment option for patients with immune checkpoint inhibitor–refractory advanced urothelial carcinoma.

Related Content

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more